Mebeverine

Oral
Gastrointestinal spasm, Irritable bowel syndrome

tab: Should be taken on an empty stomach. Swallow whole & do not chew due to unpleasant taste.
MR cap: May be taken with or without food. Swallow whole & do not break/chew.

Paralytic ileus.

Patient with cardiac dysrhythmia, specifically with partial or complete heart block, angina, or severe ischaemic heart disease. Renal and hepatic impairment. Children. Pregnancy and lactation.

Gastrointestinal disorders: Indigestion, heartburn, constipation.
General disorders and administration site conditions: General malaise.
Immune system disorders: Hypersensitivity (anaphylactic reactions).
Investigations: Decreased pulse rate.
Metabolism and nutrition disorders: Anorexia.
Nervous system disorders: Dizziness, headache.
Psychiatric disorders: Insomnia.
Skin and subcutaneous tissue disorders: Urticaria, facial oedema, angioedema, exanthema.

Symptoms: Neurological and CV symptoms. Management: Symptomatic and supportive treatment. Gastric lavage may be considered if discovered within approx 1 hour or in case of multiple intoxications.

Description:
Mechanism of Action: Mebeverine is a musculotropic antispasmodic agent with direct action on the gastrointestinal tract smooth muscle without affecting normal gut motility. The exact mechanism is unknown, but multiple mechanisms may contribute to its local effect on the gastrointestinal tract such as decrease in ion channel permeabilities, blockade of norepinephrine reuptake, local anaesthetic activity, changes in water absorption, and weak antimuscarinic and phosphodiesterase inhibitory effect.
Pharmacokinetics:
Absorption: Rapidly and completely absorbed. Time to peak plasma concentration: Main metabolite: 1 hour (conventional tab); approx 3 hours (modified-release cap).
Distribution: Enters breast milk. Plasma protein binding: 75% to albumin.
Metabolism: Completely metabolised via hydrolysis by esterases into veratric acid and mebeverine alcohol; demethylated carboxylic acid (DMAC) is the main metabolite in plasma.
Excretion: Mainly via urine (95% as metabolites). Elimination half-life: DMAC: 2.45 hours (conventional tab); 5.77 hours (modified-release cap).

Source: National Center for Biotechnology Information. PubChem Compound Summary for CID 4031, Mebeverine. https://pubchem.ncbi.nlm.nih.gov/compound/Mebeverine. Accessed Nov. 22, 2023.

Store below 30°C. Storage recommendations may vary between products. Refer to specific product guidelines.

Antispasmodics

A03AA04 - mebeverine ; Belongs to the class of synthetic anticholinergics, esters with tertiary amino group. Used in the treatment of functional bowel disorders.

Anon. Mebeverine. Lexicomp Online. Hudson, Ohio. Wolters Kluwer Clinical Drug Information, Inc. https://online.lexi.com. Accessed 19/07/2023.

Arrotex Pharmaceuticals (NZ) Limited. Mebeverine 135 mg Film-coated Tablet data sheet 19 April 2023. Medsafe. http://www.medsafe.govt.nz. Accessed 19/07/2023.

Aurobeverine MR 200 mg Modified-release Capsules, Hard (Milpharm Limited). MHRA. https://products.mhra.gov.uk. Accessed 19/07/2023.

Buckingham R (ed). Mebeverine Hydrochloride. Martindale: The Complete Drug Reference [online]. London. Pharmaceutical Press. https://www.medicinescomplete.com. Accessed 19/07/2023.

Duspatalin 135 mg Coated Tablets (Abbott Laboratories [M] Sdn. Bhd.). National Pharmaceutical Regulatory Agency - Ministry of Health Malaysia. https://www.npra.gov.my. Accessed 19/07/2023.

Duspatalin Retard 200 mg, Modified Release Capsules, Hard (Abbott Laboratories (S) Pte Ltd). MIMS Singapore. http://www.mims.com/singapore. Accessed 19/07/2023.

Joint Formulary Committee. Mebeverine Hydrochloride. British National Formulary [online]. London. BMJ Group and Pharmaceutical Press. https://www.medicinescomplete.com. Accessed 19/07/2023.

Mebeverine Hydrochloride 50 mg/5 mL Oral Suspension (Ardant Pharmaceuticals Ltd). MHRA. https://products.mhra.gov.uk. Accessed 19/07/2023.

Mebeverine Tablets 135 mg (Teva UK Limited). MHRA. https://products.mhra.gov.uk. Accessed 19/07/2023.